Trevi Therapeutics (TRVI) Stock Price, News & Analysis

Company Overview

Trevi Therapeutics, Inc. (NASDAQ: TRVI) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for pain management. The company’s research efforts are focused on creating small-molecule candidates that target key pain pathways, with the goal of improving safety and efficacy compared to existing treatments. By leveraging proprietary drug discovery platforms, Trevi aims to deliver next-generation analgesics for both acute and chronic pain indications.

Trevi’s pipeline encompasses preclinical programs and early-stage clinical trials that explore non-opioid mechanisms of action. These investigational candidates are designed to address unmet needs in neuropathic and inflammatory pain, offering potential alternatives to traditional opioid therapies. The company collaborates with academic research centers and contract research organizations to conduct pharmacology studies, toxicology assessments and first-in-human trials.

Headquartered in the United States, Trevi Therapeutics is led by an executive team with extensive experience in drug development, regulatory affairs and commercialization strategy. The company continues to advance its most promising candidates through the clinical development process, with the objective of bringing innovative pain relief options to patients and healthcare providers worldwide.

Key Stats

• Today's Range: $6.80 to $7.19
• 50-Day Range: $5.47 to $7.06
• 52-Week Range: $2.36 to $7.48
• Volume: 2.26 million shs
• Average Volume: 1.48 million shs
• Market Capitalization: $804.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.88
• Consensus Rating: Buy

Trevi Therapeutics Stock Analysis - MarketRank™

Trevi Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 207th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.7 / 5
• Analyst Rating: Buy

Consensus Rating

Trevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.30, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Trevi Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.49) to ($0.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Trevi Therapeutics is -15.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Trevi Therapeutics is -15.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Trevi Therapeutics has a P/B Ratio of 5.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.16% of the float of Trevi Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Trevi Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Trevi Therapeutics has recently decreased by 97.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Trevi Therapeutics does not currently pay a dividend.

Dividend Growth

Trevi Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.16% of the float of Trevi Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Trevi Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Trevi Therapeutics has recently decreased by 97.98%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Trevi Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

Search Interest

Only 9 people have searched for TRVI on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.

MarketBeat Follows

12 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Trevi Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.30% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TRVI Stock Analysis - Frequently Asked Questions

How have TRVI shares performed this year?

Trevi Therapeutics' stock was trading at $4.12 at the start of the year. Since then, TRVI shares have increased by 66.5% and is now trading at $6.86.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) issued its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.04.
Read the conference call transcript.

When did Trevi Therapeutics IPO?

Trevi Therapeutics (TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager.

Who are Trevi Therapeutics' major shareholders?

Top institutional shareholders of Trevi Therapeutics include Diversified Trust Co (0.02%) and Farther Finance Advisors LLC (0.01%). Insiders that own company stock include David P Meeker, Thomas Sciascia, Jennifer L Good, Farrell Simon and Lisa Delfini.
View institutional ownership trends.

How do I buy shares of Trevi Therapeutics?

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Trevi Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include JPMorgan Chase & Co. (JPM), Predictive Oncology (POAI), Ford Motor (F), Tesla (TSLA), Meta Platforms (META), Abbott Laboratories (ABT) and Bank of America (BAC).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRVI
• CIK: 1563880
• Web: www.trevitherapeutics.com
• Phone: (203) 304-2499
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Trevi Therapeutics: $20.88
• High Price Target: $29.00
• Low Price Target: $7.00
• Potential Upside/Downside: +197.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.30
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$47.91 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -58.41%
• Return on Assets: -52.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.38
• Quick Ratio: 15.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.30 per share
• Price / Book: 5.40

Miscellaneous

• Outstanding Shares: 117,290,000
• Free Float: 95,828,000
• Market Cap: $823.96 million
• Optionable: Optionable
• Beta: 0.46